Program

Program Monday, 6 November 2017

7:00 - 18:00
REGISTRATION HELP DESK HOURS (Hall 5)
Room: Hall 5
7:15 - 8:30
ISPOR NUTRITION ECONOMICS SPECIAL INTEREST GROUP OPEN MEETING
Room: Forth (Armadillo)
ISPOR members interested in nutrition economics or medical nutrition are invited to attend.  We will discuss new topics for a working group key project and provide a brief summary on our submission to Value in Health, a manuscript on Medical Nutrition – Terms, Definitions, & Regulations.  We encourage you to join us!  
7:30 - 8:30
ISPOR PATIENT REPORTED OUTCOMES RESEARCH SPECIAL INTEREST GROUP OPEN MEETING
Room: Hall 1
ISPOR is holding an open meeting to discuss the formation and selection of projects for a Patient Centered Outcome Research (PCOR) Special Interest Group. Members interested in clinical outcome assessments (COAs), including patient reported (PROs), clinician reported (ClinROs) or caregiver reported outcomes assessment (ObsROs) and performance outcome assessments (PerfOs) are invited to attend.
7:30 - 8:30
EDUCATIONAL SYMPOSIUM
7:30 - 8:30
Room: Lomond Auditorium (Loch Suite)
REAL-WORLD EVIDENCE TO SUPPORT REGULATORY APPROVALS BASED ON TUMOR BIOMARKERS IN ONCOLOGY RESEARCH

(Sponsored by Cardinal Health)

8:00 - 18:00
SPEAKER READY ROOM HOURS (Fyne-Loch Suite)
Room: Fyne (Loch Suite)
8:30 - 19:45
EXHIBIT/POSTER HALL HOURS (Hall 4)
Room: Hall 4
8:45 - 10:45
WELCOME & FIRST PLENARY SESSION
Room: Clyde Auditorium (Armadillo)
WELCOME FROM ISPOR CEO/EXECUTIVE DIRECTOR
Speaker: Nancy S. Berg
CEO & Executive Director, ISPOR, Lawrenceville, NJ, USA
Room: Clyde Auditorium (Armadillo)
PRESIDENTIAL ADDRESS
Speaker: Shelby D. Reed, PhD, RPh bio
2017-2018 ISPOR President & Professor, Duke University, Durham, NC, USA
Room: Clyde Auditorium (Armadillo)
CONGRESS PROGRAM OVERVIEW FROM PROGRAM COMMITTEE CO-CHAIRS
Speaker: Andrew Briggs, DPhil bio
William R. Lindsay Chair of Health Economics, Health Economics & Health Technology Assessment, University of Glasgow, Glasgow, UK
Speaker: Maarten J. IJzerman, PhD bio
Professor & Vice-Dean, Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands
Room: Clyde Auditorium (Armadillo)
FIRST PLENARY SESSION: WHERE IS THE VALUE IN VALUE-BASED HEALTH CARE?
There now is a wide consensus that health care products and services should be priced in relation to the additional value they produce.  While cost-effectiveness analysis explicitly assumes allocation of resources based on added societal value, practitioners and health care policymakers in European institutions now increasingly promote value-based health care (VBHC) as a more holistic, patient-centered understanding of value. Although VBHC seems well aligned with cost-effectiveness analysis, there are several fundamental differences. Where VBHC is embraced by health care practitioners and hospital administrators because of its focus on patient value over the entire care pathways instead of single interventions, it lacks an operational definition of value in relation to cost. Another difference is that outcomes in VBHC are disease-specific, which implies they cannot be used for societal resource allocation decisions. This plenary session will therefore introduce VBHC in more general terms from a clinical and hospital perspective, and then will specifically discuss the challenges and main differences with cost-effectiveness analysis from an industrial, health economics, and patient perspective.
Moderator: Maarten J. IJzerman, PhD bio
Professor & Vice-Dean, Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands
Speaker: Peter Naredi bio
Professor of Surgery & Head, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg and President, European CanCer Organization (ECCO), Brussels, Belgium
Speaker: Luke Slawomirski bio
Health Economist & Policy Analyst, Directorate for Employment, Labour and Social Affairs, Organisation for Economic Co-operation and Development (OECD), Paris, France
Speaker: Bettina Ryll, MD, PhD bio
Founder, Melanoma Patient Network Europe and Chair, Patient Advocates Working Group, European Society for Medical Oncology (ESMO), Uppsala, Sweden
Speaker: Jason Arora, BMBCh, MPH bio
Director, Value-Based Healthcare, Medtronic, London, UK
8:45 - 13:45
RESEARCH POSTER PRESENTATIONS - SESSION I
10:45 - 11:15
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I (Hall 4)
Room: Hall 4
11:15 - 12:15
BREAKOUT SESSION

11:15 - 12:15
Room: Hall 3

IP1: PRAGMATIC CLINICAL TRIALS TO ESTIMATE TREATMENT EFFECTS: ARE THEY WORTH THE EFFORT?

Moderator:

Rita M. Kristy, MS, Director - Statistics, Clinical and Outcomes Sciences, Astellas Pharma Global Development, Northbrook, IL, USA

Panelists:

Keith R. Abrams, PhD, CStat, Professor of Medical Statistics, NIHR Senior Investigator Emeritus & Head, Biostatistics Research Group, Department of Health Sciences, University of Leicester, Leicester, UK

Christoph Gerlinger, PD, Senior Director, Development, Pharmaceuticals, Bayer AG, Berlin, Germany

Helene Karcher, PhD, Managing Vice-President, Analytica Laser, Loerrach, Germany


11:15 - 12:15
Room: Clyde Auditorium (Armadillo)

IP2: HOW TO IMPROVE CONSISTENCY OF ORPHAN DRUG PRICING AND REIMBURSEMENT IN EUROPE? APPLICATION OF THE 'ORPH-VAL' PRINCIPLES IN GERMANY, FRANCE, AND THE UNITED KINGDOM

Moderator:

Lieven Annemans, PhD, MSc, Senior Full Professor of Health Economics, ICHER (Interuniversity Center for Health Economics Research), Ghent University - Brussels University, Ghent, Belgium

Panelists:

Karina Ehrig, PhD, Scientific advisor, Pharmaceuticals Department, Federal Joint Committee (G-BA), Berlin, Germany

Francois Meyer, PhD, Advisor to the President, International Affairs, Haute Autorité de Santé (HAS), Saint-Denis, France

Sheela Upadhyaya, MSc, Associate Director, Centre for Health Technology Evaluation, Highly Specialised Technologies, National Institute for Health and Care Excellence (NICE), London, UK


11:15 - 12:15
Room: Hall 2
W1: WHERE DO WE NEED GOOD RESEARCH PRACTICE GUIDANCE IN HEALTH TECHNOLOGY ASSESSMENT?
Discussion Leaders:

Finn Børlum Kristensen, MD, PhD, Professor, Faculty of Health Sciences, University of Southern Denmark, Hilleroed, Denmark bio

Mirjana Huić, MD, PhD, Assistant Director, Department for Development, Research and Health Technology Assessment, Agency for Quality and Accreditation in Health Care and Social Welfare, Zagreb, Croatia

Wim Goettsch, PhD, Director EUnetHTA JA3, EUnetHTA JA3 Directorate, The National Healthcare Institute (ZIN), Diemen, The Netherlands

Sophie Werkö, PhD, MSc, Project Director, Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), Stockholm, Sweden


11:15 - 12:15
Room: Hall 1
W2: PATIENT POWERED REGISTRIES: USEFUL FOR HEALTH TECHNOLOGY ASSESSMENT OR NOT?
Discussion Leaders:

Gurmit Sandhu, B Pharm (Hons), MBA, MPH, Patient Engagement Specialist, Gurmit Sandhu Consulting GmbH, Basel, Switzerland

Elisabeth M. Oehrlein, BA, PhD Candidate, Dept. of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA

Robert N. McBurney, PhD, Co-Principal Investigator, iConquerMS™ - the MS Patient-Powered Research Network, Accelerated Cure Project for MS, Waltham, MA, USA

Chantal Guilhaume, PharmD, Scientific Project Manager, EUnetHTA JA3; Direction de l'Evaluation Médicale, Economique et de Santé Publique (DEMESP), Haute Autorité de Santé, Saint-Denis La Plaine, France


11:15 - 12:15
Room: Lomond Auditorium (Loch Suite)
P1: COST-EFFECTIVENESS STUDIES
Moderator: Manuela A. Joore
Professor of Health Technology Assessment & Decision Making, Department of Clinical Epidemiology and Medical Technology Assessment, School for Public Health and Primary Care (CAPHRI), Maastricht, The Netherlands

CE1

11:15 - 11:30

COST-EFFECTIVENESS OF DABIGATRAN WITH REAL WORLD EFFECTIVENESS EVIDENCE

de Pouvourville G1, Guilmet C2, Cohen AA3, Le Dissez C4, Luciani L4, Le Lay K4
1ESSEC Business School, Cergy-Pontoise, France, 2MAPI Group, Nanterre, France, 3Hôpital saint Antoine, Paris, France, 4Boehringer Ingelheim France, Paris, France

CE2

11:30 - 11:45

COST-EFFECTIVENESS ANALYSIS OF MIDOSTAURIN (MIDO) WITH STANDARD CHEMOTHERAPY (SOC) FOR ACUTE MYELOID LEUKEMIA (AML) IN THE UNITED KINGDOM (UK)

Tremblay G1, Dolph M1, Patel S2, Brandt P3, Forsythe A1
1Purple Squirrel Economics, New York, NY, USA, 2Novartis Pharmaceuticals UK Limited, Camberley, Surrey, UK, 3Novartis Pharmaceuticals, East Hanover, NJ, USA

CE3

11:45 - 12:00

FIRST-LINE PEMBROLIZUMAB IN PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS FROM A UK HEALTHCARE PERSPECTIVE

Hu X, Goldman DP
University of Southern California, Los Angeles, CA, USA

CE4

12:00 - 12:15

THE EFFECTIVENESS AND COST-EFFECTIVENESS OF TOBACCO CONTROL MASS MEDIA CAMPAIGNS IN SCOTLAND

Haghpanahan H1, Boyd KA1, Mackay DF1, Mcintosh E1, Pell J1, Haw S2
1University of Glasgow, Glasgow, UK, 2University of Stirling, Stirling, UK

11:15 - 12:15
Room: Forth (Armadillo)
P2: CANCER STUDIES
Moderator: Margreet G. Franken, PhD
Senior Researcher, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands

CN1

11:15 - 11:30

USE OF NEW THERAPIES AND HOSPITAL ADMISSION NEAR THE END OF LIFE IN CASTRATION RESISTANT PROSTATE CANCER (CRPC) IN THE CASTRATION RESISTANT PROSTATE CANCER REGISTRY (CAPRI) IN THE NETHERLANDS

Kuppen M1, Westgeest H1, Van den Eertwegh A2, Gerritsen W3, Uyl - de Groot C1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2VU University Medical Centre, Amsterdam, The Netherlands, 3Radboud University Medical Center, Nijmegen, The Netherlands

CN2

11:30 - 11:45

THE GRETA STUDY: GENERATING REAL-WORLD EVIDENCE ABOUT BEVACIZUMAB TREATMENT OF METASTATIC COLORECTAL CANCER BY LINKING CANCER REGISTRIES AND HEALTHCARE DATABASES IN ITALY

Franchi M1, Caputo A2, Barni S3, De Ceglie MC4, Mazzucco W5, Ricci P6, Tagliabue G7, Tumino R8, Corrao G9
1University of Milano-Bicocca, Milano, Italy, 2Roche S.p.A., Monza, Italy, 3ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, Italy, 4Roche S.p.A, Monza, Italy, 5University of Palermo, Palermo, Italy, 6Health Protection Agency Mantua&Cremona, NHS Italy, Mantova, Italy, 7Fondazione IRCCS National Cancer Institute, Milano, Italy, 8Provincial Health Authority, ASP Ragusa, Ragusa, Italy, 9Università di Milano-Bicocca, Milan, Italy

CN3

11:45 - 12:00

ASSESSING THE CONSISTENCY IN REPORTING OF ADVERSE EVENTS ACROSS DATA SOURCES FOR MULTIPLE MYELOMA TREATMENT

Kish J, Feinberg B
Cardinal Health Specialty Solutions, Dublin, OH, USA

CN4

12:00 - 12:15

UTILIZATION AND TREATMENT PATTERNS AMONG PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER RECEIVING PREDICTIVE MOLECULAR BIOMARKER (BMX) TESTS

Kothari S1, Arunachalam A2, Tsao M3, Lee DH4, Kambartel K5, Isobe H6, Huang M7, Escosteguy Barrios CH8, Khattak A9, de Marinis F10, Cao X11, Burke T12, Lopez MA13, De Castro J14
1Merck & Co, Kenilworth, NJ, USA, 2Merck & Co., Inc., North Wales, PA, USA, 3University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada, 4Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South), 5Bethanien Hospital, Moers, Germany, 6KKR Sapporo Medical Center, Sapporo, Japan, 7Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan, 8PUCRS School of Medicine, Porto Alegre, Brazil, 9FIona Stanley Hospital, Murdoch, Australia, 10European Institute of Oncology, Milan, Italy, 11Merck & Co, Inc, Kenilworth, NJ, USA, 12Merck & Co., Inc., Lebanon, NJ, USA, 13MSD, Madrid, Spain, 14Hospital Universitario La Paz, MADRID, Spain
12:15 - 14:15
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I (Hall 4)
Room: Hall 4
12:30 - 13:30
ISPOR DIGEST OF DATABASES SPECIAL INTEREST GROUP OPEN MEETING
Room: Hall 1
All ISPOR members and regional chapters interested in learning about or updating the ISPOR Digest of Databases are welcome to attend. This meeting will provide background information and objectives in updating the ISPOR Digest of Databases, an electronic index (digest) of 400 databases from 45 countries consisting of key attributes of health care databases. The goal is to encourage and enlist the assistance of the audience to understand the importance of providing access to up-to-date research organization information.
12:45 - 13:45
ISPOR STUDENT RESEARCH SHOWCASE
Room: Lomond Auditorium (Loch Suite)
This showcase session will feature three outcomes research studies, conducted by ISPOR student members and presented during the European Congress. A brief summary of the research study and conclusions will be presented by each student author followed by discussion.
Moderator: Zeba M. Khan, MS, RPh, PhD
Vice President, Celgene Corporation, Summit, NJ, USA
Moderator: Laura Pizzi, MPH, RPh, PharmD
Professor and Director, Center for Health Outcomes, Policy & Economics, Rutgers University, Ernest Mario School of Pharmacy, New Brunswick, NJ, USA
Speaker: Junjie Ma, Msc
Student, University of Utah, Salt Lake City, UT, USA
Speaker: Omer Ben-Aharon, MBA, MHA
Student, Bar-Ilan University, Bar-Ilan University, Ramat Gan, Israel
Speaker: Fanni Soikkeli
Student, University of Eastern Finland, Joensuu, Kuopio and Savonlinna, Finland
12:45 - 13:45
EDUCATIONAL SYMPOSIUM
12:45 - 13:45
Room: Clyde Auditorium (Armadillo)
HTA V2.0: THE RELEVANCE OF REAL-WORLD EVIDENCE IN VALUE FRAMEWORKS AND ITS RELATION WITH REGULATORY AND HEALTH TECHNOLOGY ASSESSMENT CONVERGENCE

(Sponsored by QuintilesIMS)

12:45 - 13:45
POSTER AUTHOR DISCUSSION HOUR - SESSION I (Hall 4)
Room: Hall 4
14:15 - 15:15
BREAKOUT SESSION

14:15 - 15:15
Room: Hall 2

IP3: UNMET (MEDICAL) NEED: SHOULD STAKEHOLDERS ALIGN ON A DEFINITION?

Moderator:

Claudine Sapede, PharmD, MSc, Global HTA & Payment Policy Lead, F. Hoffmann-La Roche Ltd, Basel, Switzerland

Panelists:

Nicola Bedlington, Secretary General, European Patients’ Forum and Co-Founder, The Patient Access Partnership PACT, Brussels, Belgium

Neil McAuslane, PhD, Director, Center for Innovation in Regulatory Science, London, UK

Jo De Cock, MS, Administrateur General, INAMI - Institut National de l'Assurance Maladie-Invalidité, Brussels, Belgium


14:15 - 15:15
Room: Clyde Auditorium (Armadillo)

IP4: VALUE ADDED MEDICINES: TIME TO ADJUST THE HEALTH TECHNOLOGY ASSESSMENT DECISION FRAMEWORKS?

Moderator:

Michael Drummond, MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK bio

Panelists:

Ulf Persson, PhD, Professor, The Swedish Institute for Health Economics (IHE), Lund, Sweden

Luigi Burgio, MSc, Head of Market Access & Government Affairs, Market Access, Teva Italia S.r.l., Assago (MI), Italy

Mondher Toumi, MD, PhD, MSc, Professor, Public Health, Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille University, Marseille, France


14:15 - 15:15
Room: Hall 3
W3: MAKING PATIENT REPORTED OUTCOMES MEASUREMENT MEANINGFUL: BEST PRACTICES FOR PRESENTING PATIENT REPORTED OUTCOMES DATA TO PATIENTS, CLINICIANS, AND DECISION MAKERS
Discussion Leaders:

Jakob B. Bjorner, MD, PhD, CSO, Optum Patient Insights, Johnston, RI, USA

Michael Brundage, FRCPC, MD, Professor and Director, Division of Cancer Care and Epidemiology, Cancer Research Institute, Queen's University, Kingston, ON, Canada

Claire Snyder, MHS, PhD, Professor of Medicine and Program Director, Johns Hopkins School of Medicine, Baltimore, MD, USA

Martha Bayliss, MSc, CSO, Optum Patient Insights, Johnston, RI, USA


14:15 - 15:15
Room: Forth (Armadillo)
W4: BRIDGING THE GAP: BEST PRACTICES IN NAVIGATING DIVERGING PERCEPTIONS OF REGULATORS AND PAYERS ON NON-TRADITIONAL CLINICAL TRIAL ENDPOINTS
Discussion Leaders:

Mark Chalmers, PhD, Principal & EU Lead, CBPartners, London, UK

Caroline Solon, MSc, Senior Associate, CBPartners, San Francisco, CA, USA

Andrew Walker, PhD, Director, Salus Alba Consulting, Glasgow, UK

Lung-I Cheng, PhD, Director, Market Access, Takeda, Zurich, Switzerland


14:15 - 15:15
Room: Lomond Auditorium (Loch Suite)
P3: STUDIES ON HEALTH TECHNOLOGY ASSESSMENT AGENCIES
Moderator: Allan Wailoo, PhD
Professor of Health Economics,, University of Sheffield and Director, NICE Decision Support Unit, Sheffield, UK

HT1

14:15 - 14:30

PLAYING IN THE SAME POND - THE IMPACT OF BREXIT ON CLINICAL TRIALS AND ACCESS

Wang GD, Macaulay R
PAREXEL International, London, UK

HT2

14:30 - 14:45

HEALTH TECHNOLOGY ASSESSMENT DECISIONS IN IMMUNO-ONCOLOGY THERAPIES: RESULTS, RATIONALES, AND TRENDS

Campbell CM, Nguyen VB, Clark RS, Meyer KL
Xcenda, LLC, Palm Harbor, FL, USA

HT3

14:45 - 15:00

ANALYSIS OF FACTORS INFLUENCING THE LEVEL OF ACTUAL BENEFIT IN HEALTH TECHNOLOGY ASSESSMENT

Bouschon M1, Li J2, Barthelemy C3
1Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France, 2Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France, 3Assisance Publique des Hôpitaux de Paris (AP-HP), Paris, France

HT4

15:00 - 15:15

USING REAL-WORLD DATA (RWD) IN HEALTH TECHNOLOGY ASSESSMENT (HTA) PRACTICE: A COMPARATIVE STUDY OF 5 HTA AGENCIES

Makady A1, van Veelen A2, Jonsson P3, Moseley O4, D'Andon A5, de Boer A2, Hillege JL6, Klungel O2, Goettsch W7
1The National Healthcare Institute (ZIN), Diemen, The Netherlands, 2Utrecht University, Utrecht, The Netherlands, 3National Institute for Health and Care Excellence (NICE), Manchester, UK, 4Scottish Medicines Consortium, 50 West Nile Street, UK, 5French National Authority for Health, Saint Denis La Plaine, France, 6University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, 7Utrecht University, UTRECHT, The Netherlands

14:15 - 15:15
Room: Hall 1
P4: RESEARCH ON METHODS
Moderator: Andrea Manca
Professor, Centre for Health Economics, University of York, Heslington, York, UK

RM1

14:15 - 14:30

NETWORK META-ANALYSIS OF HAZARD RATIOS VS. FRACTIONAL POLYNOMIALS APPROACH IN A COST-EFFECTIVENESS ANALYSIS CONSIDERING ADVANCED GASTRIC CANCER

Cranmer HL, Harvey RC
Tolley Health Economics Ltd., Buxton, UK

RM2

14:30 - 14:45

MULTIVARIATE NETWORK META-ANALYSIS OF SURVIVAL FUNCTION PARAMETERS

Cope S1, Chan K1, Jansen JP2
1Precision Health Economics, Vancouver, BC, Canada, 2Precision Health Economics, Los Angeles, CA, USA

RM3

14:45 - 15:00

METHODS FOR EXTRACTING TREATMENT PATTERNS FOR RENAL CELL CARCINOMA (RCC) FROM SOCIAL MEDIA (SM) FORUMS USING NATURAL LANGUAGE PROCESSING (NLP) AND MACHINE LEARNING (ML)

Merinopoulou E1, Ramagopalan S2, Malcolm B2, Cox A1
1Evidera, London, UK, 2Bristol-Myers Squibb, Uxbridge, UK

RM4

15:00 - 15:15

NON-PROPORTIONAL HAZARDS IN NETWORK META-ANALYSIS: EFFICIENT STRATEGIES FOR MODEL BUILDING AND ANALYSIS

Gsteiger S1, Windisch R1, Bryden P1, Wiksten A2
1F. Hoffmann-La Roche Ltd, Basel, Switzerland, 2StatFinn & EPID Research, Espoo, Finland
15:00 - 16:00
CAREER ADVICE ACROSS THE GLOBE - THE ART OF GETTING PUBLISHED
Room: Alsh (Loch Suite)
Career Advice Across The Globe made its debut at the 22nd Annual International Meeting in Boston and provides both New Professional and soon-to-graduate Student members with the opportunity to hear first-hand experiences from established ISPOR members. “The Art of Getting Published” will focus on good practices and tips to consider when submitting research for publishing.
Speaker: Lyn Beamesderfer
Associate Director, Publications & Communications, International Society for Pharmacoeconomics and Outcomes Research, Lawrenceville, NJ, USA
Speaker: C. Daniel Mullins, PhD
Professor & Chair, Pharmaceutical Health Services Research, University of Maryland, School of Pharmacy, Baltimore, MD, USA
Speaker: Diego Rosselli, MSc, MEd, MD
Associate Professor, Pontificia Universidad Javeriana, Bogota, Colombia
Speaker: Dan Greenberg, PhD
Associate Professor & Chairman, Department of Health Systems Management, Ben-Gurion University of the Negev, Beer-Sheva, Israel
15:15 - 15:45
BREAK & EXHIBITS VIEWING (Hall 4)
Room: Hall 4
15:45 - 16:45
BREAKOUT SESSION

15:45 - 16:45
Room: Hall 2

IP5: EUROPEAN HTA 2020: WHAT IS THE ROAD MAP TO EFFECTIVE PERMANENT COOPERATION? (INVITED ISSUE PANEL)

Moderator:

Tim Wilsdon, Msc, Vice President London Office, Charles Rivers Associates, London, UK

Panelists:

Wim Goettsch, PhD, Director, EUnetHTA JA3 Directorate, The National Healthcare Institute (ZIN), Diemen, The Netherlands

Adrian Griffin, MSc, Vice President, HTA & Reimbursement Policy, Johnson & Johnson, Buckinghamshire, UK

Nicola Bedlington, BA Hons, Secretary General, European Patients Forum (EPF), Brussels, Belgium

Flora Giorgio, Head of Sector, Health Technology Assessment, Directorate General for Health and Food Safety (DG SANTE), European Commission, Brussels, Belgium


15:45 - 16:45
Room: Hall 3

IP6: ARE EXISTING HEALTH TECHNOLOGY ASSESSMENT REQUIREMENTS INADEQUATE FOR ESTABLISHING VALUE FOR POTENTIALLY TRANSFORMATIVE GENE THERAPIES?

Moderator:

Kellie Meyer, PharmD, MPH, Senior Director, Global Health Economics, Xcenda, Palm Harbor, FL, USA

Panelists:

Ron Akehurst, PhD, Chairman, BresMed Health Solutions, Sheffield, UK

Clark Paramore, MSPH, Head of Value Demonstration, bluebird bio, Cambridge, MA, USA

Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, UK


15:45 - 16:45
Room: Lomond Auditorium (Loch Suite)
W5: SUSTAINABLE FUNDING AND FAIR PRICING FOR ORPHAN DRUGS: WHAT ARE THE SOLUTIONS?
Discussion Leaders:

Martina Garau, MSc, Principal Economist, Office of Health Economics, London, UK

Michael Drummond, MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK bio

Saskia Knies, PhD, Senior Advisor Pharmacoeconomics, National Health Care Institute (ZiN), Diemen, The Netherlands

Olivier Ponet, MBA, Region Europe VD&A Lead, Shire plc, Zug, Switzerland


15:45 - 16:45
Room: Clyde Auditorium (Armadillo)
W6: GENERATING REAL-WORLD EVIDENCE FOR REAL-WORLD DECISIONS: APPLICATION OF ADVANCED METHODS
Discussion Leaders:

Mark Sculpher, PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK

Richard Grieve, PhD, Professor of Health Economics Methodology, London School of Hygiene and Tropical Medicine, London, UK

Anirban Basu, PhD, Professor & Director, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA

Stephen Oneill, MEconSc, PhD, Lecturer, Economics, National University of Ireland, Galway, Galway, Ireland


15:45 - 16:45
Room: Hall 1
P5: MEDICATION ADHERENCE STUDIES
Moderator: Maureen Rutten-van Mölken, PhD
Associate Professor, School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands

AD1

15:45 - 16:00

EXPLORING FACTORS EXPLAINING TREATMENT ACCEPTANCE IN PATIENTS SUFFERING FROM A CHRONIC DISEASE

Wiederkehr S1, de Bock E2, Chekroun M3, Arnould B4
1Mapi, Patient Centered Sciences, Lyon, France, 2Mapi, Patient-Centered Outcomes, Lyon, France, 3Carenity, Paris, France, 4Mapi, Patient Centered Outcomes, Lyon, France

AD2

16:00 - 16:15

THE IMPACT OF PHARMACIST-LED MEDICATION THERAPY MANAGEMENT ON MEDICATION ADHERENCE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A RANDOMIZED CONTROLLED STUDY

Erku DA, Belachew SA, Tegegn HG, Ayele AA
University of Gondar, Gondar, Ethiopia

AD3

16:15 - 16:30

FACTORS ASSOCIATED WITH AN ADHERENCE WITH ANTIEPILEPTIC DRUGS IN CHILDREN TREATED IN PEDIATRIC PRACTICES IN GERMANY

Kostev K1, Dombrowski S1, Jacob L2
1QuintilesIMS, Frankfurt am Main, Germany, 2University of Paris 5, Paris, France

AD4

16:30 - 16:45

PREDICTIVE ANALYSIS FOR IDENTIFYING PATIENT CHARACTERISTICS ASSOCIATED WITH PRIMARY MEDICATION NONADHERENCE FOR LIPID LOWERING THERAPIES

Hill JW1, Rane PB2, Hines DM1, Patel J2, Harrison DJ2, Wade RL1
1QuintilesIMS, Plymouth Meeting, PA, USA, 2Amgen Inc., Thousand Oaks, CA, USA

15:45 - 16:45
Room: Forth (Armadillo)
P6: MENTAL HEALTH STUDIES
Moderator: Rok Hren, PhD, MSc, IHP (HE)
Assistant Professor, University of Ljubljana, Ljubljana, Slovenia

MH1

15:45 - 16:00

DISCRETE EVENT SIMULATION MODELLING OF LONG TERM COST-EFFECTIVENESS OF INTERNET-BASED BLENDED COGNITIVE BEHAVIOURAL THERAPY FOR MAJOR DEPRESSIVE DISORDER: EXTRAPOLATION OF THE E-COMPARED RANDOMISED CONTROLLED TRIAL.

O'Connell MM1, Kolovos S2, Bosmans JE2, Forbes JF1, E-COMPARED Consortium .3
1University of Limerick, Limerick, Ireland, 2Vrije Universiteit Amsterdam, Amsterdam, The Netherlands, 3E-COMPARED Consortium, Europe, Ireland

MH2

16:00 - 16:15

ADHERENCE PATTERNS AMONG PATIENTS USING ORAL ATYPICAL ANTIPSYCHOTICS AND OTHER MEDICATIONS

Shafrin J1, Lakdawalla DN2, MacEwan JP1, Silverstein AR1, Hatch A3, Forma F4
1Precision Health Economics, Los Angeles, CA, USA, 2University of Southern California, Los Angeles, CA, USA, 3ODH, Inc., Princeton, NJ, USA, 4Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA

MH3

16:15 - 16:30

MODEL STRUCTURE OF PATIENT-LEVEL MODELS FOR SCHIZOPHRENIA: A SYSTEMATIC LITERATURE REVIEW

Zhou J1, Millier A2, Dorey J2, Aballéa S2, Toumi M1
1Aix-Marseille University, Marseille, France, 2Creativ-Ceutical, Paris, France

MH4

16:30 - 16:45

FAMILY CAREGIVING IN DEMENTIA AND ITS IMPACT ON QUALITY OF LIFE AND ECONOMIC BURDEN IN JAPAN – WEB-BASED SURVEY

Igarashi A1, Fukuda A1, Teng L1, Ma F2, Dorey J3, Onishi Y4
1University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan, 2Creativ-Ceutical, Beijing, China, 3Creativ-Ceutical, Paris, France, 4Creativ-Ceutical K.K., Tokyo, Japan
15:45 - 19:30
RESEARCH POSTER PRESENTATIONS - SESSION II
17:00 - 18:00
BREAKOUT SESSION

17:00 - 18:00
Room: Clyde Auditorium (Armadillo)

IP7: 'MIND THE GAP!': HOW SHOULD WE MANAGE THE DIFFERENCE BETWEEN REGULATORY AND REIMBURSEMENT EVIDENCE REQUIREMENTS FOR MEDICAL DEVICES?

Moderator:

Bjoern Schwander, RN, BSc, MA, General Manager, Agency for Health Economic Assessment and Dissemination, AHEAD GmbH, Loerrach, Germany

Panelists:

Richard Charter, MSc, Head of Market Access & Pricing, EMEA, Becton Dickinson, Basel, Switzerland

Karen Facey, PhD, Honorary Research Fellow and Evidence Based Healthcare Policy Consultant, University of Edinburgh, Edinburgh, UK

Nneka C. Onwudiwe, PhD, PharmD, MBA, PRO/PE Regulatory Review Officer, U.S. Government, Silver Spring, MD, USA


17:00 - 18:00
Room: Lomond Auditorium (Loch Suite)

IP8: FORECASTING PHARMACEUTICAL EXPENDITURE IN EUROPE: IS IT SUSTAINABLE?

Moderator:

Jorge Mestre-Ferrandiz, PhD, Economist, Independent Economics Consultant, Madrid, Spain

Panelists:

Tim Davis, MSc, Senior Principle, Consulting, QuintilesIMS, Basel, Switzerland

Claudio Jommi, PhD, Associate Professor, Department of Pharmaceutical Sciences, Università del Piemonte Orientale, Cergas (Centre for Research on Health and Social Care Management), SDA Bocconi School of Management, Milano, Italy

Panos Kanavos, PhD, Associate Professor in International Health Policy, LSE Health, Medical Technology Research Group, London School of Economics and Political Science, London, UK


17:00 - 18:00
Room: Hall 2
W7: VALUE OF INFORMATION (VOI) ANALYSIS FOR RESEARCH DECISIONS: EMERGING GOOD PRACTICE RECOMMENDATIONS FROM THE ISPOR VOI TASK FORCE
Discussion Leaders:

Elisabeth Fenwick, PhD, Senior Principal, Health Economics, Health Economics & Epidemiology, ICON plc, Abingdon, UK

Saskia Knies, PhD, Senior Advisor Pharmacoeconomics, National Health Care Institute (ZiN), Diemen, The Netherlands

Hendrik Koffijberg, PhD, Associate Professor Health Economics, Health Technology & Services Research, University of Twente, Enschede, The Netherlands

Claire Rothery, PhD, Senior Research Fellow, Centre for Health Economics, University of York, York, UK


17:00 - 18:00
Room: Hall 3
W8: MODELING SEPARATE LINES OF TREATMENT VERSUS TREATMENT SEQUENCES IN CANCER
Discussion Leaders:

Agnes Benedict, MSc, Executive Director, Evidera, Budapest, Hungary

Matthew Stevenson, PhD, Professor of Health Technology Assessment, School of Health and Related Research, University of Sheffield, Sheffield, UK

Sonja Sorensen, MPH, Senior Director, Senior Research Leader, Modeling & Simulation, Evidera, Bethesda, MD, USA


17:00 - 18:00
Room: Hall 1
P7: CONCEPTUAL PAPERS
Moderator: Andrej Srakar, PhD
Research Associate, Institute for Economic Research (IER), Ljubljana, Assistant Professor, Faculty of Economics, University of Ljubljana, Ljubljana, Slovenia

CP1

17:00 - 17:15

INNOVATIVE PRICING AND REIMBURSEMENT SCHEMES – THE WHAT, WHY, WHICH, AND HOW

Macaulay R, Hettle R
PAREXEL International, London, UK

CP2

17:15 - 17:30

USING OUTCOME DATA TO INFORM HEALTHCARE PROFESSIONAL – PATIENT DISCUSSION: A DATABASE OF TREATMENT EFFECTS

Gilbert J
National Guideline Centre, London, UK

CP3

17:30 - 17:45

THE FUTURE OF PRECISION MEDICINE: WHAT DOES IT MEAN FOR NICE?

Rejon-Parrilla JC1, Lovett RE2, Chalkidou A3, Love-Koh J4, Wood H4, Ennis K4, Peel A4, Taylor M4
1National Institute for Health and Care Excellence (NICE), Manchester, UK, 2National Institute for Health and Care Excellence (NICE), London, UK, 3King's Technology Evaluation Centre (KiTEC), King's College London, London, UK, 4York Health Economics Consortium, University of York, York, UK

CP4

17:45 - 18:00

CHALLENGES IN OPTIMISING REAL WORLD EVIDENCE FOR ALZHEIMER’S DISEASE

Reed C1, de Reydet de Vulpillieres F2, Gallacher J3
1Eli Lilly and Company Ltd, Windlesham, UK, 2NOVARTIS PHARMA AG, Basel, Switzerland, 3Oxford University, Oxford, UK

17:00 - 18:00
Room: Forth (Armadillo)
P8: CARDIOVASCULAR STUDIES
Moderator: Olivia Wu, PhD, MSc
Professor of Health Technology Assessment, Director of HEHTA, Director of NIHR Complex Reviews Support Unit, Institute of Health and Wellbeing, University of Glasgow, Health Economics and Health Technology Assessment (HEHTA) , Glasgow, UK

CV1

17:00 - 17:15

INTERIM RESULTS OF A MULTI-COUNTRY SURVEY TO EVALUATE PRODUCTIVITY LOSS AND INDIRECT COSTS AFTER CARDIOVASCULAR EVENTS IN EUROPE

Gerlier L1, Sidelnikov E2, Kutikova L2, Lamotte M1, Amarenco P3, Kotseva K4, Annemans L5
1QuintilesIMS, Zaventem, Belgium, 2Amgen (Europe) GmbH, Zug, Switzerland, 3Bichat Hospital-Claude Bernard, Paris, France, 4National Heart & Lung Institute, Imperial College London, London, UK, 5Ghent University - Brussels University, Ghent, Belgium

CV2

17:15 - 17:30

A FRAMEWORK FOR THE COST-EFFECTIVENESS ANALYSIS OF NOVEL BIOMARKER TESTING IN CARDIOVASCULAR DISEASE

Kohli-Lynch CN, Boyd K, Briggs A, Delles C
University of Glasgow, Glasgow, UK

CV3

17:30 - 17:45

CYP2C19 GUIDED ANTIPLATELET THERAPY: A COST-EFFECTIVENESS ANALYSIS OF 30-DAY AND ONE-YEAR OUTCOMES FOLLOWING PERCUTANEOUS CORONARY INTERVENTION

Dong OM1, Borse MS1, Polasek MJ2, Farley JF1, Stouffer GA1, Lee CR1
1University of North Carolina, Chapel Hill, NC, USA, 2QuintilesIMS, Durham, NC, USA

CV4

17:45 - 18:00

COST MODEL FOR A NEW ACOUSTIC DIAGNOSTIC AID TO RULE OUT CORONARY ARTERY DISEASE

Winther S1, Böttcher M2, Wahler S3, Bolin K4
1Aarhus University Hospital, Aarhus N, Denmark, 2Hjertemedicin Hjerteforskningsklinikken, Herning, Denmark, 3St. Bernward GmbH, Hamburg, Germany, 4University of Gothenburg, Gothenburg, Sweden
18:00 - 19:45
EXHIBITORS' OPEN HOUSE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II (Hall 4)
Room: Hall 4

ISPOR wishes to thank the Lord Provost & Glasgow City Council for their ongoing assistance, and for their generosity in providing a special welcome drink at Monday evening Exhibitor Reception.

18:15 - 19:15
BREAKOUT SESSION

18:15 - 19:15
Room: Hall 3
F1: BETTER, CHEAPER, FASTER: A REPORT ON THE SCIENCE OF OPTIMIZATION FROM THE ISPOR OPTIMIZATION TASK FORCE
Moderator:

Alec Morton, PhD, Professor of Management Science, Department of Management Science, Strathclyde Business School, University of Strathclyde, Glasgow, Scotland, UK

Speakers:

Nasuh Buyukkaramikli, PhD, Scientific Researcher, Institute of Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands

Praveen Thokala, MASc, PhD, Research Fellow, The University of Sheffield, Sheffield, UK

Jon Tosh, MSc, PhD, Senior Health Economist, DRG Abacus, Manchester, UK


18:15 - 19:15
Room: Hall 2
F2: METHODS AND PRELIMINARY RESULTS OF THE ISPOR ONCOLOGY HEALTH ECONOMIC MODELING SPECIAL INTEREST GROUP
Moderator:

Noemi Muszbek, MSc, Senior Research Scientist, Evidera, London, UK

Speakers:

Agnes Benedict, MSc, Executive Director, Evidera, Budapest, Hungary

Nermeen Nabil Ashoush, PhD, Lecturer in Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, The British University in Egypt, Cairo, Egypt

Hena Qureshi, BSc BA, Student, Community Health Sciences, University of Calgary, Calgary, AB, Canada


18:15 - 19:15
Room: Clyde Auditorium (Armadillo)
F3: RARE DISEASE RESEARCH, HTA AND EVIDENCE FOR REIMBURSEMENT
Moderator:

Sandra Nestler-Parr, PhD, MPhil, MSc, Managing Director, Rare Access Ltd., London, UK

Speakers:

Ken Redekop, PhD, Associate Professor, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands

Christopher M. Blanchette, PhD, MBA, Associate Professor, University of North Carolina, Charlotte, NC, USA & VP, Precision Health Economics, Charlotte, NC, USA

Sheela Upadhyaha, BSc, Associate Director Highly Specialised Technologies, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence, London, UK

Janis Clayton, BSc, VP and General Manager UK & Ireland, PTC Therapeutics Ltd., Dublin, Ireland


18:15 - 19:15
Room: Hall 1
F4: COULD MULTI-STAKEHOLDER PARTNERSHIP IMPROVE PATIENT ACCESS TO BETTER HEALTHCARE IN LATIN AMERICA?
Moderator:

Ramiro E. Gilardino, MD, MSc, Director, Global Networks Latin America, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), Lawrenceville, NJ, USA

Speakers:

Diego F Guarin, MD, MPH, MA, Senior Director, HEOR & HTA Strategy, HEOR & HTA, Latin America, Merck-Serono, Billerica, MA, USA

Diego Rosselli, MD, Associate Professor, Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Bogota, Colombia

Federico Augustovski, MD, MSc, PhD, Director, Health Technology Assessment & Economic Evaluations Department, Institute for Clinical Effectiveness and Health Policy (IECS), Professor of Public Health, University of Buenos Aires, Buenos Aires, Argentina

Nicola Bedlington, Secretary General, European Patients’ Forum and Co-Founder, The Patient Access Partnership PACT, Brussels, Belgium


18:15 - 19:15
Room: Lomond Auditorium (Loch Suite)
F5: RARE DISEASES MCDA CRITERIA IMPLEMENTATION RESULTS IN EUROPEAN COUNTRIES
Moderator:

Olha Zaliska, PhD, DSci (Pharm), Professor, The Head of Department of Management & Economy of Pharmacy and Medicine Technology, Postgraduate Faculty, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

Speakers:

John Yfantopoulos, PhD, President, ISPOR Greece Chapter, Professor, Health Economics, University of Athens, Athens, Greece

Francesco Saverio Mennini, MSc, Professor of Health Economics and Research Director, Professor of Health Economics and Research Director, CEIS Economic Evaluation and HTA (EEHTA), University Tor Vergata Roma, Rome, Italy

Tarik Catic, PhD(s), Consultant, Health Economics and Pharmacoeconomics, Sarajevo, Bosnia

Rok Hren, PhD, MSc, President, ISPOR Slovenia Chapter, Assistant Professor, Institute of Mathematics, Physics and Mechanics, Ljubljana, Slovenia


18:15 - 19:15
Room: Forth (Armadillo)
F6: THE ESTABLISHMENT OF NEGOTIATION COMMITTEE, THERAPEUTIC GUIDELINES AND HEALTH TECHNOLOGY ASSESSMENT EFFORTS IN CEE COUNTRIES
Moderator:

Magda Hatzikou, PhD, Managing Partner, PharmEcons Easy Access Ltd, Athens, Greece

Speakers:

Zoltan Kalo, PhD, Professor of Health Economics, Eötvös Loránd University (ELTE), Founder & CEO, Syreon Research Institute, Budapest, Hungary

Dragana Atanasijevic, MD, MSc, President, ISPOR Serbia Chapter, Senior Researcher, Institute of Public Health of Serbia, Belgrade, Serbia

Joanna Lis, PhD, Adjunct, Faculty of Pharmacy, Department of Pharmacoeconomics, Medical University of Warsaw, Director, Market Access, Sanofi, Warsaw, Poland

Mary Geitona, MD, Professor, Health Economics, Department of Social and Educational Policy, University of Peloponnese, Korinthos, Greece

18:15 - 19:15
ISPOR STATED PREFERENCE METHODS SPECIAL INTEREST GROUP OPEN MEETING
Room: Boisdale (Loch Suite)
If you are interested in stated preference research, join us for this session that will present the new ISPOR Special Interest Group (SIG) format as well as discuss new projects and leadership opportunities. Please join us and bring your suggestions and topics that you would to see the SIG develop!
18:30 - 19:30
POSTER AUTHOR DISCUSSION HOUR - SESSION II (Hall 4)
Room: Hall 4
19:45 - 21:00
ISPOR STUDENT AND NEW PROFESSIONALS MIXER
Room: Mezzanine
All students, faculty, and new professionals are welcome to attend! One of the main goals of ISPOR is to foster personal and professional development of the future leaders in HEOR. Since launching the New Professional membership, we look to continue this mission by bridging the gap between students and more seasoned practitioners. Please join us for the first Student and New Professional Mixer for increased networking connections!
19:45 - 21:00
ISPOR CENTRAL & EASTERN EUROPE (CEE) CONSORTIUM RECEPTION
Room: Gala Foyer (Armadillo)
ISPOR is happy to announce formal recognition of the CEE Network as the ISPOR CEE Consortium! We welcome ISPOR colleagues to join us to celebrate this occasion, to interact, share ideas, and network! ISPOR CEE Consortium connects over 3700 HEOR professionals from 23 ISPOR Regional Chapters sharing ISPOR values and supporting its vision and mission. All attendees interested in learning about the ISPOR CEE Consortium, its role in the HEOR community, current activities and initiatives, are welcome to attend this event. For more information visit www.ispor.org >> Regional Chapters/Networks >> ISPOR Networks Index >> CEE Consortium.
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.